secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2026-04-17T23:59:59+00:00
Accession:  0001367644-26-000038
Event type: debt
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 1.02, 3.02, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions closes $150M Term Loan with OrbiMed, extends maturities, cuts interest expense 200 bps
--------------------------------------------------------------------------------

- New $150M Term Loan with OrbiMed matures April 2031, replaces prior $150M OHA facility; ABL reduced to $50M.
- Interest expense on Term Loan reduced by 200 basis points annually (Term SOFR + 6.25%, floor 3%).
- Delayed draw term loan of $75M available for 24 months for acquisitions/growth capex.
- Maturities extended to April 2031 from August 2029 (Term Loan) and Sept 2029 (ABL).
- Company expects lower interest expense and enhanced flexibility to support transformation plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764426000038/0001367644-26-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764426000038/ebs-20260416.htm
  HTML page:      https://secwatch.observer/filing/0001367644-26-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer